20/07/2017 ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES
(WorldNews Belgium)

REGULATED INFORMATION ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES GHENT, Belgium, 20 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a research collaboration and global exclusive licensing agreement with Sanofi initially focused on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune- mediated inflammatory diseases. This collaboration gives Sanofi access to certain Nanobodies in Ablynx`s existing portfolio as well as to Ablynx`s scientists and proprietary Nanobody platform. Under the terms of the...